Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV

This publication has 22 references indexed in Scilit:

• Antiretroviral Treatment of Adult HIV Infection
  JAMA, 2008
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
  The Lancet, 2007
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
  The Lancet, 2007
• TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments
  Journal of Virology, 2005
• From 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to Etravirine (TMC125): Fifteen Years of Research on Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
  Journal of Medicinal Chemistry, 2005
• TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1
  Antimicrobial Agents and Chemotherapy, 2004
• Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants
  Journal of Medicinal Chemistry, 2004
• Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase
  Proceedings of the National Academy of Sciences, 2001
• Progress and Problems in the Fight against AIDS
  New England Journal of Medicine, 1998
• Characterization of Highly Immunogenic p66/p51 as the Reverse Transcriptase of HTLV-III/LAV
  Science, 1986